🇺🇸 DAC in United States
78 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 78
Most-reported reactions
- Pain — 11 reports (14.1%)
- Anxiety — 10 reports (12.82%)
- Fatigue — 8 reports (10.26%)
- Nausea — 8 reports (10.26%)
- Pulmonary Embolism — 8 reports (10.26%)
- Emotional Distress — 7 reports (8.97%)
- Fall — 7 reports (8.97%)
- Pneumonia — 7 reports (8.97%)
- Death — 6 reports (7.69%)
- Diarrhoea — 6 reports (7.69%)
DAC in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is DAC approved in United States?
DAC does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for DAC in United States?
dr hab. n. med. Agnieszka Wierzbowska is the originator. The local marketing authorisation holder may differ — check the official source linked above.